Biological Roles of Hepatitis B Viral X Protein in the Viral Replication and Hepatocarcinogenesis.


Journal

Acta medica Okayama
ISSN: 0386-300X
Titre abrégé: Acta Med Okayama
Pays: Japan
ID NLM: 0417611

Informations de publication

Date de publication:
Aug 2023
Historique:
medline: 29 8 2023
pubmed: 28 8 2023
entrez: 27 8 2023
Statut: ppublish

Résumé

Hepatitis B virus is a pathogenic virus that infects 300 million people worldwide and causes chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Hepatitis B virus encodes four proteins. Among them, the HBx protein plays a central role in the HBV pathogenesis. Because the HBx protein is considered to play a central role in the induction of viral replication and hepatocarcinogenesis, the regulation of its function could be a key factor in the development of new interventions against hepatitis B. In this review, HBx protein-related viral replication and hepatocarcinogenesis mechanisms are described, with a focus on the recently reported viral replication mechanisms related to degradation of the Smc5/6 protein complex. We also discuss our recent discovery of a compound that inhibits HBx protein-induced degradation of the Smc5/6 protein complex, and that exerts inhibitory effects on both viral replication and hepatocarcinogenesis. Finally, prospects for future research on the HBx protein are described.

Identifiants

pubmed: 37635133
doi: 10.18926/AMO/65739
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

341-345

Déclaration de conflit d'intérêts

No potential conflict of interest relevant to this article was reported.

Références

Decorsière A, Mueller H, van Breugel PC, Abdul F, Gerossier L, Beran RK, Livingston CM, Niu C, Fletcher SP, Hantz O and Strubin M: Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor. Nature (2016) 531: 386-389.
Feitelson MA, Arzumanyan A, Spector I and Medhat A: Hepatitis B x (HBx) as a Component of a Functional Cure for Chronic Hepatitis B. Biomedicines (2022) 10: 2210.
Jeng WJ, Papatheodoridis GV and Lok ASF: Hepatitis B. Lancet (2023) in press.
Levrero M and Zucman-Rossi J: Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol (2016) 64: S84-S101.
Li F, Cheng L, Murphy CM, Reszka-Blanco NJ, Wu Y, Chi L, Hu J and Su L: Minicircle HBV cccDNA with a Gaussia luciferase reporter for investigating HBV cccDNA biology and developing cccDNA-targeting drugs. Sci Rep (2016) 6: 36483.
Minor MM, Hollinger FB, McNees AL, Jung SY, Jain A, Hyser JM, Bissig KD and Slagle BL: Hepatitis B Virus HBx Protein Mediates the Degradation of Host Restriction Factors through the Cullin 4 DDB1 E3 Ubiquitin Ligase Complex. Cells (2020) 9: 834.
Murphy CM, Xu Y, Li F, Nio K, Reszka-Blanco N, Li X, Wu Y, Yu Y, Xiong Y and Su L: Hepatitis B Virus X Protein Promotes Degradation of SMC5/6 to Enhance HBV Replication. Cell Rep (2016) 16: 2846-2854.
Pollicino T and Caminiti G: HBV-Integration Studies in the Clinic: Role in the Natural History of Infection. Viruses (2021) 13: 368.
Qiao L, Wu Q, Lu X, Zhou Y, Fernández-Alvarez A, Ye L, Zhang X, Han J, Casado M and Liu Q: SREBP-1a activation by HBx and the effect on hepatitis B virus enhancer II/core promoter. Biochem Biophys Res Commun (2013) 432: 643-649.
Rossignol JF and Bréchot C: A Pilot Clinical Trial of Nitazoxanide in the Treatment of Chronic Hepatitis B. Hepatol Commun (2019) 3: 744-747.
Sekiba K, Otsuka M, Funato K, Miyakawa Y, Tanaka E, Seimiya T, Yamagami M, Tsutsumi T, Okushin K, Miyakawa K, Ryo A and Koike K: HBx-induced degradation of Smc5/6 complex impairs homologous recombination-mediated repair of damaged DNA. Journal of Hepatology (2022) 76: 53-62.
Sekiba K, Otsuka M, Ohno M, Yamagami M, Kishikawa T, Seimiya T, Suzuki T, Tanaka E, Ishibashi R, Funato K and Koike K: Pevonedistat, a Neuronal Precursor Cell-Expressed Developmentally Down-Regulated Protein 8-Activating Enzyme Inhibitor, Is a Potent Inhibitor of Hepatitis B Virus. Hepatology (2019) 69: 1903-1915.
Sekiba K, Otsuka M, Ohno M, Yamagami M, Kishikawa T, Suzuki T, Ishibashi R, Seimiya T, Tanaka E and Koike K: Inhibition of HBV Transcription From cccDNA With Nitazoxanide by Targeting the HBx-DDB1 Interaction. Cell Mol Gastroenterol Hepatol (2019) 7: 297-312.
Yang, L Zou T, Chen Y, Zhao Y, Wu X, Li M, Du F, Xiao Z and Shen J: Hepatitis B virus X protein mediated epigenetic alterations in the pathogenesis of hepatocellular carcinoma. Hepatol Int (2022) 16: 741-754.
Yuan H, Zhao L, Yuan Y, Yun H, Zheng W, Geng Y, Yang G, Wang Y, Zhao M and Zhang X: HBx represses WDR77 to enhance HBV replication by DDB1-mediated WDR77 degradation in the liver. Theranostics (2021) 11: 8362-8378.
Zhang Z, Torii N, Hu Z, Jacob J and Liang TJ: X-deficient woodchuck hepatitis virus mutants behave like attenuated viruses and induce protective immunity in vivo. J Clin Invest (2001) 108: 1523-1531.

Auteurs

Motoyuki Otsuka (M)

Department of Gastroenterology and Hepatology, Academic Field of Medicine, Density and Pharmaceutical Sciences, Okayama University.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH